SCHEMBL5135939

SCHEMBL5135939

CCCCC(c1cnc(-c2ccccc2)n1CCCC)N(CCCC)Cc1cccc(OC)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
CRHR1 P34998 3/20 0.38
GAA P10253 1/20 0.38
F2R P25116 3/20 0.38
TLR7 Q9NYK1 1/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.37
CALM1 P0DP23 1/20 0.36
CAMKK2 Q96RR4 1/20 0.36
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
CNR2 P34972 1/20 0.36
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5137583 0.95 HSP90AA1 (0.39) HSP90AA1HSP90AB1CRHR1GAAF2R
SCHEMBL5071417 0.90 TSHR (0.39) HSP90AA1CRHR1GAAMAPTTSHR
SCHEMBL5137324 0.89 ACHE (0.36) TLR7TSHR
SCHEMBL5135184 0.87 TSHR (0.38) TLR7TSHRNR1H3
SCHEMBL5136148 0.87 OPRK1 (0.40) TLR7TSHRNR1H2NR1H3
SCHEMBL5137842 0.87 MEN1 (0.40) HSP90AA1HSP90AB1GAAF2RTLR7
SCHEMBL5134552 0.86 TSHR (0.40) CRHR1GAAMAPTTSHR
SCHEMBL5135309 0.85 TLR7 (0.41) TLR7
SCHEMBL5135388 0.84 CXCR3 (0.38) CRHR1TSHR
SCHEMBL5135943 0.83 C5AR1 (0.36) TSHRCHRM2CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed